Your browser doesn't support javascript.
loading
Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report.
Wu, Sarah J; Kim, Justin J; Huang, Yeying; Durall, R Taylor; Becker, Simone; Canty, Stephanie; Molinaro, Stefania; Pisick, Evan; Shapiro, Geoffrey I; French, Christopher A; Luo, Jia.
Afiliación
  • Wu SJ; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Kim JJ; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Huang Y; Department of Biology, Colby College, Waterville, Massachusetts.
  • Durall RT; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Becker S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Canty S; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Molinaro S; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Pisick E; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Shapiro GI; City of Hope Chicago, Zion, Illinois.
  • French CA; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Luo J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
JTO Clin Res Rep ; 5(1): 100625, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38287941
ABSTRACT
We present the first known case of a patient with BRD2NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: JTO Clin Res Rep Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: JTO Clin Res Rep Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos